

# CITATION REPORT

List of articles citing

Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies

DOI: 10.1177/0961203310395803

Lupus, 2011, 20, 206-18.

**Source:** <https://exaly.com/paper-pdf/50193903/citation-report.pdf>

**Version:** 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
441	Rheumatologic Diseases and Strokes. 389-407		
440	Antiphospholipid syndrome: coming of age. <b>2011</b> , 7, 151-153		
439	Antiphospholipid syndrome: coming of age. <b>2011</b> , 7, 151-3		
438	Therapeutic Perspectives in the Antiphospholipid Syndrome. <b>2011</b> , 7, 313-321		
437	Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. <b>2011</b> , 9, 1657-9		68
436	Strategies for managing heparin therapy in patients with antiphospholipid antibody syndrome. <b>2011</b> , 31, 1221-31		17
435	Management of refractory anti-phospholipid syndrome. <b>2011</b> , 10, 669-73		40
434	Systemic lupus erythematosus - an update. <b>2011</b> , 49, 81-4		3
433	OBSTETRIC ANTIPHOSPHOLIPID SYNDROME - A REVIEW. <b>2011</b> , 22, 265-286		
432	Primary prevention in antiphospholipid antibody carriers. <i>Lupus</i> , <b>2012</b> , 21, 751-4	2.6	16
431	Neurology and Pregnancy. <b>2012</b> ,		
430	Antiphospholipid antibody syndrome. <b>2012</b> , 23, 528-32		11
429	Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome. <b>2012</b> , 24, 473-81		22
428	Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. <b>2012</b> , 38, 339-47		28
427	Pathogenesis of the antiphospholipid syndrome. <b>2012</b> , 38, 305-21		58
426	[Antiphospholipid-syndrome - when to treat?]. <b>2012</b> , 137, 1748-50		1
425	Antiphospholipid syndrome-associated nephropathy in systemic lupus erythematosus. <b>2012</b> , 7, 131-134		1

424	Secondary prevention in thrombotic antiphospholipid syndrome. <i>Lupus</i> , <b>2012</b> , 21, 734-5	2.6	10
423	Current world literature. <b>2012</b> , 23, 562-71		
422	Syndrome des anticorps antiphospholipides. <b>2012</b> , 7, 1-4		
421	Immunomodulatory approaches to the management of antiphospholipid syndrome. <b>2012</b> , 7, 1-4		
420	[Internal medicine and neurological diseases: progress in diagnosis and treatment topics: X. Neurological disorders in connective tissue disease]. <b>2012</b> , 101, 2242-8		
419	Venous thromboembolic disease in systemic autoimmune diseases: an association to keep in mind. <b>2012</b> , 12, 289-94		10
418	¿Se deben tratar preventivamente los pacientes asintomáticos con anticuerpos antifosfolípidos?. <b>2012</b> , 13, 147-151		1
417	[Management of antiphospholipid syndrome]. <b>2012</b> , 33, 217-22		4
416	[The antiphospholipid syndrome in 2012: its heterogeneity requires personalized care]. <b>2012</b> , 33, 173-5		1
415	Recurrent venous thromboembolism while on anticoagulant therapy. <b>2012</b> , 26, 175-81		10
414	[Neuropsychiatric systemic lupus erythematosus (1st part). Cases definitions and diagnosis and treatment of central nervous system and psychiatric manifestations of systemic lupus erythematosus]. <b>2012</b> , 33, 491-502		10
413	Prevention and Treatment of Venous and Arterial Thrombosis in Patients with Specific Conditions: Diabetes, Hypercoagulable States, Pregnancy, and Renal Insufficiency. <b>2012</b> , 327-356		
412	Late-onset systemic lupus erythematosus: epidemiology, diagnosis and treatment. <b>2012</b> , 29, 181-189		54
411	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <b>2012</b> , 71, 1771-82		692
410	Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. <i>Lupus</i> , <b>2012</b> , 21, 1183-9	2.6	39
409	22 Erworbene Thrombophilie. <b>2012</b> ,		
408	36 Antikoagulanzen. <b>2012</b> ,		
407	Splenic infarction, warm autoimmune hemolytic anemia and antiphospholipid antibodies in a patient with infectious mononucleosis. <b>2012</b> , 95, 573-6		14

406	Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: "Pros" and "Cons". <b>2012</b> , 11, 568-71	19
405	High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. <b>2012</b> , 11, 577-80	25
404	Much more than thrombosis and pregnancy loss: the antiphospholipid syndrome as a 'systemic disease'. <b>2012</b> , 26, 79-90	16
403	Antiphospholipid syndrome in obstetrics. <b>2012</b> , 26, 65-76	45
402	[Diagnosis and treatment of lupus nephritis]. <b>2012</b> , 212, 147.e1-30	3
401	Beyond the "syndrome": antiphospholipid antibodies as risk factors. <b>2012</b> , 64, 342-5	17
400	Management of obstetric antiphospholipid syndrome. <b>2012</b> , 14, 79-86	23
399	The management of stroke in antiphospholipid syndrome. <b>2012</b> , 14, 99-106	23
398	Hughes Syndrome: Highways and Byways. <b>2013</b> ,	1
397	Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. <b>2013</b> , 56, 358-61	36
396	Anti- $\beta$ -glycoprotein I antibodies. <b>2013</b> , 1285, 44-58	26
395	Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop?. <b>2013</b> , 15, 318	7
394	Vena cava filters for management of venous thromboembolism: a clinical review. <b>2013</b> , 27, 225-41	40
393	Improving outcomes in patients with lupus and end-stage renal disease. <b>2013</b> , 26, 590-6	15
392	The significance of antiphospholipid antibodies in liver recipients. <b>2013</b> , 45, 1983-9	10
391	Antiphospholipid antibodies in renal allograft recipients. <b>2013</b> , 45, 1655-60	7
390	Traitement du lupus systémique. <b>2013</b> , 34, A12-A17	
389	[Primary antiphospholipid syndrome: newly developed leg ulcer and history of stroke]. <b>2013</b> , 64, 666-70	

388	Thrombin generation as marker to estimate thrombosis risk in patients with abnormal test results in lupus anticoagulant routine diagnostics. <b>2013</b> , 11, 24		6
387	The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , <b>2013</b> , 9, 659-68	5.1	5
386	Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. <b>2013</b> , 12, 752-7		52
385	Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. <i>Lupus</i> , <b>2013</b> , 22, 6-17	2.6	48
384	Diretrizes para o tratamento da síndrome do anticorpo antifosfolípido. <b>2013</b> , 53, 184-192		13
383	Thrombotic recurrences and bleeding events in APS vascular patients: a review from the literature and a comparison with the APS Piedmont Cohort. <b>2013</b> , 12, 826-31		20
382	Síndrome antifosfolípido. <b>2013</b> , 11, 1975-1980		
381	Guidelines for the treatment of antiphospholipid syndrome. <b>2013</b> , 53, 184-192		3
380	Transmetatarsal amputation in the setting of antiphospholipid antibody syndrome. <b>2013</b> , 52, 383-8		1
379	Statins and autoimmunity. <b>2013</b> , 56, 348-57		50
378	Antiphospholipid Syndrome. <b>2013</b> , 681-689		
377	Clinical advances of interest in the diagnosis and treatment of patients with antiphospholipid syndrome. <b>2013</b> , 213, 108-13		5
376	Antiphospholipid syndrome. <i>Hematology American Society of Hematology Education Program</i> , <b>2013</b> , 2013, 675-80	3.1	52
375	Traitement du lupus érythémateux systémique. <b>2013</b> , 73-90		
374	Pathogenesis and treatment of CNS lupus. <b>2013</b> , 25, 577-83		42
373	Cardiac valve vegetations in APS, role of long-term anticoagulation. <i>Lupus</i> , <b>2013</b> , 22, 223-5	2.6	0
372	Aspirin resistance in systemic lupus erythematosus. A pilot study. <i>Lupus</i> , <b>2013</b> , 22, 835-8	2.6	7
371	Syndrôme des antiphospholipides. <b>2013</b> , 241-259		

370	Should low molecular weight heparin dosing be based on anti-Xa assays in antiphospholipid syndrome?. <b>2013</b> , 24, 82-4		
369	GAPSS: the Global Anti-Phospholipid Syndrome Score. <b>2013</b> , 52, 1397-403		170
368	Thromboembolism risk following recurrent miscarriage. <b>2013</b> , 11, 1503-13		2
367	Submassive pulmonary embolism: where's the tipping point?. <b>2013</b> , 127, 2458-64		3
366	Could statins be a new therapeutic option for antiphospholipid syndrome patients?. <b>2013</b> , 6, 115-7		5
365	Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. <b>2013</b> , 122, 817-24		86
364	Antiphospholipid Antibody Syndrome. <b>2013</b> , 55-64		
363	[Libman-Sacks endocarditis associated with antiphospholipid syndrome. Report of one case]. <b>2013</b> , 141, 1206-10		1
362	Cardiopulmonary Disease in SLE. <b>2013</b> , 352-362		
361	Thrombotic antiphospholipid syndrome shows strong haplotypic association with SH2B3-ATXN2 locus. <b>2013</b> , 8, e67897		15
360	Thrombophilia in Systemic Lupus Erythematosus: A Review of Multiple Mechanisms and Resultant Clinical Outcomes. <b>2013</b> ,		
359	Special aspects in the treatment of systemic lupus erythematosus. <b>2013</b> , 3, 210-214		
358	Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. <b>2014</b> , 112, 947-50		77
357	. <b>2014</b> ,		
356	The beneficial effect of plasmapheresis in mixed connective tissue disease with coexisting antiphospholipid syndrome. <i>Lupus</i> , <b>2014</b> , 23, 1079-84	2.6	4
355	Thrombotic risk in the antiphospholipid syndrome. <b>2014</b> , 40, 741-6		13
354	Anti-phospholipid antibodies. <b>2014</b> , 53, 201-2		4
353	Intracardiac multiple thrombus formation as a rare manifestation of primary antiphospholipid antibody syndrome: a case report. <i>Lupus</i> , <b>2014</b> , 23, 721-3	2.6	1

352	Antiphospholipid syndrome in renal transplantation. <b>2014</b> , 19, 177-85		19
351	Predictors of long-term recurrent vascular events after ischemic stroke at young age: the Italian Project on Stroke in Young Adults. <b>2014</b> , 129, 1668-76		75
350	Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome. <i>Lupus</i> , <b>2014</b> , 23, 913-8	2.6	13
349	The future of treatment for antiphospholipid syndrome. <b>2014</b> , 9, 41-57		
348	Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome. <b>2014</b> , 133, 936-44		21
347	Treatment of the antiphospholipid syndrome. <b>2014</b> , 5, 1-7		10
346	Summary of the 9th meeting of the European Forum on Antiphospholipid Antibodies. <i>Lupus</i> , <b>2014</b> , 23, 395-9	2.6	4
345	Management of recurrent thrombosis in antiphospholipid syndrome. <b>2014</b> , 16, 405		22
344	Antiphospholipid syndrome. <b>2014</b> , 42, 156-161		3
343	Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. <b>2014</b> , 13, 595-608		123
342	Renal involvement in antiphospholipid syndrome. <b>2014</b> , 10, 279-89		65
341	The chequered history of the antiphospholipid syndrome. <b>2014</b> , 165, 609-17		14
340	Fitting and flailing: recognition of paediatric antiphospholipid syndrome. <b>2014</b> , 99, 28-36		5
339	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. <b>2014</b> , 13, 281-91		112
338	Diagnosis and classification of the antiphospholipid syndrome. <b>2014</b> , 48-49, 20-5		176
337	[Antiphospholipid syndrome in nephrology. Kidney damage and practical aspects of the management]. <b>2014</b> , 10, 1-9		1
336	[Assessing the cardiovascular risk in patients with systemic lupus erythematosus]. <b>2014</b> , 35, 723-9		4
335	New oral anticoagulants in thrombotic antiphospholipid syndrome. <i>Lupus</i> , <b>2014</b> , 23, 1279-82	2.6	31

334	Acquired Thrombophilia. <b>2014</b> , 27, 234-42		11
333	The mTORC pathway in the antiphospholipid syndrome. <b>2014</b> , 371, 369-71		12
332	Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <b>2014</b> , 45, 2160-236		2808
331	An update on current management strategies for antiphospholipid syndrome-related thrombosis. <b>2014</b> , 9, 91-100		1
330	[Arteriovenous thrombosis as a first sign of antiphospholipid syndrome in an octogenarian patient]. <b>2014</b> , 49, 43-5		
329	Moyamoya syndrome with antiphospholipid antibodies: a case report and literature review. <i>Lupus</i> , <b>2014</b> , 23, 1204-6	2.6	6
328	Current treatment strategies for management of antiphospholipid syndrome. <b>2014</b> , 2, 205-215		
327	Antithrombotic treatment for stroke associated with antiphospholipid antibodies. <b>2014</b> , 7, 169-72		5
326	Venous thromboembolism and antithrombotic therapy in pregnancy. <b>2014</b> , 36, 527-53		160
325	Syndr�me des antiphospholipides et manifestations thrombotiques art�rielles c�r�brales et coronariennes : Etude r�trospective chez les patients de moins de 50 ans. <b>2015</b> , 36, A116-A117		
324	Right Atrial Thrombosis in Antiphospholipid Syndrome with Secondary Immune Thrombocytopenia. <b>2015</b> , 4, 40-3		2
323	Cerebral Venous Thromboembolism in Antiphospholipid Syndrome Successfully Treated with the Combined Use of an Anti-Xa Inhibitor and Corticosteroid. <b>2015</b> , 54, 3051-6		15
322	Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches. <b>2015</b> , 2015, 951424		37
321	Manifestations neurologiques centrales du syndrome des anticorps antiphospholipides. <b>2015</b> , 6, 245-253		
320	Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio. <b>2015</b> , 40, 293-300		23
319	What is the best strategy in treating catastrophic antiphospholipid syndrome?. <b>2015</b> , 10, 245-255		3
318	Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response. <b>2015</b> , 136, 1174-8		19
317	Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis. <b>2015</b> , 55, 1-21		3



316	Antiphospholipid Syndrome of Late Onset: A Difficult Diagnosis of a Recurrent Embolic Stroke. <b>2015</b> , 24, e209-11		12
315	Antiphospholipid syndrome, antiphospholipid antibodies and solid organ transplantation. <i>Lupus</i> , <b>2015</b> , 24, 1356-63	2.6	7
314	Current treatment of antiphospholipid syndrome: lights and shadows. <b>2015</b> , 11, 586-96		78
313	Strokes and vision: The management of ischemic arterial disease affecting the retina and occipital lobe. <b>2015</b> , 60, 296-309		17
312	The therapeutic value of laboratory testing for hypercoagulable states in secondary stroke prevention. <b>2015</b> , 33, 501-13		7
311	Difficult clinical situations in the antiphospholipid syndrome. <b>2015</b> , 17, 29		13
310	Inferior vena cava filters: current best practices. <b>2015</b> , 39, 315-27		12
309	Pediatric antiphospholipid syndrome. <b>2015</b> , 17, 27		26
308	[Antiphospholipid syndrome]. <b>2015</b> , 74, 191-8		0
307	The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome. <b>2015</b> , 17, 16		19
306	Reviewing the recommendations for lupus in children. <b>2015</b> , 17, 17		9
305	Treatment Algorithms in Systemic Lupus Erythematosus. <b>2015</b> , 67, 1237-1245		67
304	First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2015</b> , 24, 1045-56	2.6	44
303	Antiphospholipid syndrome: an update. <b>2015</b> , 45, 653-62		25
302	Rituximab in antiphospholipid syndrome: Always, never, sometimes?. <b>2015</b> , 144, 115-117		
301	Antiphospholipid Syndrome and the Kidney. <b>2015</b> , 35, 478-86		54
300	[Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis]. <b>2015</b> , 55, 1-21		30
299	Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. <b>2015</b> , 14, 192-200		86

298	[Screening and management of cardiovascular risk factors in systemic lupus erythematosus: Recommendations for clinical practice based on the literature and expert opinion]. <b>2015</b> , 36, 372-80		7
297	[Rituximab in antiphospholipid syndrome: always, never, sometimes?]. <b>2015</b> , 144, 115-7		1
296	Antiphospholipid Antibody Syndrome. <b>2015</b> ,		1
295	Recurrent myocardial infarctions and premature coronary atherosclerosis in a 23-year-old man with antiphospholipid syndrome. <b>2016</b> , 115, 237-9		12
294	Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis. <b>2016</b> , 11, e0158757		19
293	Hypercoagulability in Kidney Transplant Recipients. <b>2016</b> , 100, 719-26		30
292	[Antiphospholipid syndrome]. <b>2016</b> , 75, 570-4		2
291	Antiphospholipid Syndrome. <b>2016</b> , 269-281		
290	Pediatric Antiphospholipid Syndrome. <b>2016</b> , 11, 385-408		
289	Prevention of thrombosis in antiphospholipid syndrome. <i>Hematology American Society of Hematology Education Program</i> , <b>2016</b> , 2016, 707-713	3.1	7
288	[Pregnancy in systemic autoimmune diseases: Myths, certainties and doubts]. <b>2016</b> , 147, 306-12		6
287	Renal involvement in primary antiphospholipid syndrome. <b>2016</b> , 29, 507-15		8
286	Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?. <b>2016</b> , 18, 26		10
285	Systemic Lupus Erythematosus and Antiphospholipid Syndrome. <b>2016</b> , 183-198		
284	Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine. <b>2016</b> , 53 Suppl 1, S48-50		13
283	Current status and future prospects for the treatment of antiphospholipid syndrome. <i>Expert Review of Clinical Immunology</i> , <b>2016</b> , 12, 927-35	5.1	7
282	[Systemic lupus erythematosus]. <b>2016</b> , 141, 537-43		5
281	Unusual Cause of Adrenal Insufficiency. <b>2016</b> , 129, e177-9		2

280	Clinical implications of the detection of antibodies directed against domain 1 of $\beta$ -glycoprotein 1 in thrombotic antiphospholipid syndrome. <b>2016</b> , 148, 32-37		5
279	Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. <b>2016</b> , 3, e426-36		231
278	Pregnancy in systemic autoimmune diseases: Myths, certainties and doubts. <b>2016</b> , 147, 306-312		
277	Prevalence and predictors of valvular heart disease in patients with systemic lupus erythematosus. <b>2016</b> , 15, 1134-1140		13
276	The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. <b>2016</b> , 74, 41-72		95
275	Recognition and management of antiphospholipid syndrome. <b>2016</b> , 28, 51-9		20
274	[Hereditary thrombophilia testing and its therapeutic impact on venous thromboembolism disease: Results from a retrospective single-center study of 162 patients]. <b>2016</b> , 37, 661-666		2
273	Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. <b>2016</b> ,		4
272	Antiphospholipid Syndrome. <b>2016</b> , 318-335.e10		4
271	Patients with antiphospholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study). <i>Lupus</i> , <b>2016</b> , 25, 479-85	2.6	31
270	Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS). <b>2016</b> , 22, 239-47		66
269	Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature. <b>2016</b> , 15, 226-35		47
268	Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. <b>2016</b> , 76, 459-83		91
267	Childhood Lupus--Diagnosis and Management. <b>2016</b> , 83, 146-55		1
266	Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity. <b>2016</b> , 13, 163-78		13
265	Antiphospholipid syndrome presenting as cerebral venous sinus thrombosis: a case series and a review. <b>2016</b> , 69, 337-43		10
264	Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. <i>Lupus</i> , <b>2016</b> , 25, 301-6	2.6	60
263	Primary Prophylaxis in Patients With Positive Antiphospholipid Antibodies. <b>2017</b> , 221-229		

262	Treatment of Thrombosis in Antiphospholipid Syndrome. <b>2017</b> , 12, 231-241	
261	Antiphospholipid syndrome. <b>2017</b> , 151 Suppl 1, S43-S47	128
260	Acute myocardial infarction and antiphospholipid antibody syndrome: a systematic review. <b>2017</b> , 28, 332-335	30
259	Antiphospholipid Syndrome: Role of Vascular Endothelial Cells and Implications for Risk Stratification and Targeted Therapeutics. <b>2017</b> , 69, 2317-2330	72
258	Broad Concepts in Management of Systemic Lupus Erythematosus. <b>2017</b> , 92, 744-761	10
257	Cessation of oral anticoagulants in antiphospholipid syndrome. <i>Lupus</i> , <b>2017</b> , 26, 1347-1348	2.6
256	Cavernous sinus thrombosis in a patient with nephrotic syndrome. <b>2017</b> , 6, 136-139	1
255	Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. <b>2017</b> , 44, 1165-1172	35
254	Antiphospholipid Syndrome. <b>2017</b> ,	3
253	Pathogenesis and management of antiphospholipid syndrome. <b>2017</b> , 178, 181-195	56
252	The adjusted Global Antiphospholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. <b>2017</b> , 240, 72-77	30
251	Cessation of oral anticoagulants in antiphospholipid syndrome. <i>Lupus</i> , <b>2017</b> , 26, 1291-1296	2.6 13
250	Diagnosis and treatment of antiphospholipid syndrome in childhood: A review. <b>2017</b> , 67, 34-40	14
249	Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. <b>2017</b> ,	3
248	Paediatric Antiphospholipid Syndrome. <b>2017</b> , 12, 145-165	1
247	Impact of thrombophilia screening on venous thromboembolism management practices. <b>2017</b> , 149, 76-80	9
246	Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. <b>2017</b> , 10, CD012169	10
245	Could Anticoagulation or Antiaggregation Treatment Be Ceased in Patients With Primary Antiphospholipid Syndrome When Antiphospholipid Antibodies Become Persistently Negative?. <b>2017</b> , 23, 350-353	1

244	Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's. <b>2017</b> , 16, 1103-1108		11
243	Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconversion?. <b>2017</b> , 16, 1109-1114		11
242	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)? The unmet needs and the clinical grey zone in autoimmune disease management. <b>2017</b> , 16, 911-924		84
241	Diagnosis and management of the antiphospholipid syndrome. <b>2017</b> , 31, 406-417		71
240	Hematologic Abnormalities and Acute Lung Syndromes. <b>2017</b> ,		2
239	The antiphospholipid syndrome in patients with systemic lupus erythematosus. <b>2017</b> , 76, 10-20		91
238	Thrombophilias and Acute Pulmonary Thromboembolic Disease. <b>2017</b> , 89-108		
237	Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. <b>2017</b> , 65, 17-24		58
236	Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. <i>Lupus</i> , <b>2017</b> , 26, 163-169	2.6	34
235	Antiphospholipid Syndrome: Multiple Manifestations in a Single Patient-A High Suspicion Is Still Needed. <b>2017</b> , 2017, 5797041		2
234	Anti-phospholipid Syndrome. <b>2017</b> , 1389-1399		1
233	. <b>2017</b> , 16, 140-149		3
232	Rivaroxaban for Thromboprophylaxis in Patients with Antiphospholipid Syndrome. <b>2017</b> , 24, 108		
231	Treatment of Systemic Lupus Erythematosus. <b>2017</b> , 1368-1388.e5		3
230	Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. <b>2017</b> , 1, 2320-2324		24
229	Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium. <b>2018</b> , 131, 2097-2110		29
228	Reduced plasma fibrin clot permeability is associated with recurrent thromboembolic events in patients with antiphospholipid syndrome. <b>2018</b> , 57, 1340-1349		10
227	Use of direct oral anticoagulants in antiphospholipid syndrome. <b>2018</b> , 16, 1028-1039		31

226	The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. <b>2018</b> , 90, 1-27		46
225	Uso de inhibidores directos del factor Xa en síndrome antifosfolípido: una serie de 7 casos. <b>2018</b> , 25, 16-21		1
224	Antiphospholipid syndrome. <b>2018</b> , 4, 17103		128
223	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <b>2018</b> , 57, e1-e45		150
222	La ricerca del lupus anticoagulant: raccomandazioni del gruppo di studio sulla coagulazione di SIPMeL. <b>2018</b> , 14, 156-164		
221	Update on Antiphospholipid Syndrome: Ten Topics in 2017. <b>2018</b> , 20, 15		19
220	Primary antiphospholipid syndrome presenting with homonymous quadrantanopsia. <b>2018</b> , 10, 208-210		2
219	Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. <i>Haematologica</i> , <b>2018</b> , 103, e315-e317	6.6	18
218	Management of Thrombotic Antiphospholipid Syndrome. <b>2018</b> , 44, 419-426		21
217	[Laboratory diagnosis of antiphospholipid syndrome: From criteria to practice]. <b>2018</b> , 39, 34-41		3
216	Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study. <i>Lupus</i> , <b>2018</b> , 27, 357-364	2.6	8
215	The Antiphospholipid Syndrome. <b>2018</b> , 2088-2101		
214	Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study. <b>2018</b> , 38, 229-238		2
213	Thrombotic antiphospholipid syndrome. <i>Lupus</i> , <b>2018</b> , 27, 21-27	2.6	2
212	Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2971	8.4	37
211	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <b>2018</b> , 4, e000785		21
210	The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome. <b>2018</b> , 6, 362		13
209	Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy. <b>2018</b> , 9, 1001		35

208	Improvement of Cardiac Vegetations in Antiphospholipid Syndrome with Enoxaparin and Corticosteroids after Rivaroxaban Failure. <b>2018</b> , 2018, 8097539		1
207	Obstetric antiphospholipid syndrome. <b>2018</b> , 5, e000197		25
206	Use of factor Xa inhibitors in antiphospholipid antibodies syndrome: A series of seven cases. <b>2018</b> , 25, 16-21		
205	Neurologic manifestations of antiphospholipid syndrome. <i>Lupus</i> , <b>2018</b> , 27, 1404-1414	2.6	28
204	Antiphospholipid Antibody Induced by Nivolumab. <b>2018</b> , 2018, 3106852		5
203	Antiphospholipid Syndrome. <b>2018</b> , 305-321		
202	Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner. <b>2018</b> , 5, 161		26
201	Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective. <b>2018</b> , 169, 35-40		22
200	Hypercoagulable Workup in Thrombotic Cardiovascular Diseases. <b>2018</b> , 138, 229-231		3
199	Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. <b>2018</b> , 7, CD012534		19
198	Improvement of Libman-Sacks Endocarditis With Combined Hydroxychloroquine-Vitamin K Antagonist Therapy in a Primary Antiphospholipid Syndrome Patient. <b>2018</b> , 82, 2380-2382		3
197	Extensive abdominal wall ulceration as a late manifestation of antiphospholipid syndrome: a case report. <b>2018</b> , 12, 226		4
196	Antibodies against TFPI and protein C are associated with a severe thrombotic phenotype in patients with and without antiphospholipid syndrome. <b>2018</b> , 170, 60-68		4
195	A case of extreme weight loss due to mesenteric ischemia and antiphospholipid syndrome. <b>2018</b> , 6, 1055-1059		2
194	Successful Endovascular Treatment for Aortic Thrombosis Due to Primary Antiphospholipid Syndrome: A Case Report and Literature Review. <b>2019</b> , 53, 51-57		5
193	Stroke and antiphospholipid syndrome-antiphospholipid antibodies are a risk factor for an ischemic cerebrovascular event. <b>2019</b> , 38, 379-384		11
192	Recurrent Thrombosis With Direct Oral Anticoagulants in Antiphospholipid Syndrome: A Systematic Literature Review and Meta-analysis. <b>2019</b> , 41, 1839-1862		17
191	Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1948	8.4	17

190 Antiphospholipid Syndrome. **2019**, 45-49

189 Preclinical and early systemic lupus erythematosus. **2019**, 33, 101422

9

188 Neurorheumatology. **2019**,

1

187 Management of Antiphospholipid Syndrome in Patients with Systemic Lupus Erythematosus. **2019**, 5, 190-200

186 Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies. **2019**, 45, 468-477

12

185 Antiphospholipid syndrome: a clinical review. **2019**, 211, 184-188

9

184 Trombosis obstructiva de prótesis mecánica mitral en paciente con síndrome antifosfolípido. **2019**, 26, 289-292

183 Antiphospholipid antibodies in patients with lupus nephritis: clinical correlations and associations with long-term outcomes. *Lupus*, **2019**, 28, 1460-1467

2.6

1

182 Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A real-life study. **2019**, 41, 738-744

4

181 Can we use NOACS in APS?. **2019**, 18, 102408

3

180 Potential usefulness of activated charcoal (DOAC remove ) for dRVVT testing in patients receiving Direct Oral AntiCoagulants. **2019**, 184, 86-91

20

179 Das Antiphospholipidsyndrom. **2019**, 39, 37-43

178 A challenging case of neuropsychiatric systemic lupus erythematosus with recurrent antiphospholipid- related stroke: A case report and literature review. **2019**, 11, 8182

177 Ischemic Stroke From Libman-Sacks Endocarditis Not Associated With Antiphospholipid Antibodies: Good Clinical Outcome Without Anticoagulation. **2019**, 1, 297-300

176 The diagnostic utility of routine clot analysis after endovascular thrombectomy in a patient with systemic lupus erythematosus and antiphospholipid syndrome. **2019**, 70, 247-249

3

175 Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. **2019**, 17, 645-656

50

174 Oral surgery in patients with antiphospholipid syndrome. **2019**, 61, 386-390

173 EULAR recommendations for the management of antiphospholipid syndrome in adults. **2019**, 78, 1296-1304

312



172	High prevalence of inherited thrombophilia and antiphospholipid syndrome in myocardial infarction with non-obstructive coronary arteries: Comparison with cryptogenic stroke. <b>2019</b> , 290, 1-6	16
171	Antiphospholipid Syndrome. <b>2019</b> , 483-492	
170	Rare case of catastrophic antiphospholipid syndrome with spontaneous intracranial haemorrhage. <b>2019</b> , 12,	4
169	Antiphospholipid Syndrom. <b>2019</b> , 18, 12-15	
168	Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS). <b>2019</b> , 12,	
167	[Lupus nephritis]. <b>2019</b> , 15, 174-189	2
166	Unresolved questions on venous thromboembolic disease. Consensus statement of the French Society for Vascular Medicine (SFMV). <b>2019</b> , 44, 28-70	
165	[Unresolved questions on venous thromboembolic disease. Consensus statement of the French Society for Vascular Medicine (SFMV)]. <b>2019</b> , 44, e1-e47	2
164	Neurological Complications in Patients with Systemic Lupus Erythematosus. <b>2019</b> , 19, 97	22
163	Antiphospholipid syndrome in pediatric patients. <b>2019</b> , 26, 366-371	7
162	Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome. <b>2019</b> , 30, 669-675	
161	Prevention of arterial thrombosis recurrence in anti-phospholipid syndrome: are anti-platelets the answer?. <b>2019</b> , 58, 935-936	0
160	Clinical Aspects of Antiphospholipid Syndrome. <b>2019</b> , 532-542	
159	Clinical and immunological features of antiphospholipid syndrome in the elderly: a retrospective national multicentre study. <b>2019</b> , 58, 1006-1010	7
158	Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome. <b>2019</b> , 82, 53-61	1
157	Under crossfire: thromboembolic risk in systemic lupus erythematosus. <b>2019</b> , 58, 940-952	13
156	New therapeutic strategies in systemic lupus erythematosus management. <b>2019</b> , 15, 30-48	58
155	Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome. <b>2019</b> , 58, 969-974	13

154 Antiphospholipid Syndrome. **2019**, 655-667

153 Thrombophilia: Clinical and Laboratory Assessment and Management. **2019**, 242-265

1

152 Use of Vena Cava Filters and Venous Access Devices. **2019**, 594-635

151 Antiphospholipid Syndrome. **2019**, 374-395

150 Management of antiphospholipid syndrome. **2019**, 78, 155-161

49

149 Preeclampsia in pregnancies complicated by systemic lupus erythematosus (SLE) nephritis: prophylactic treatment with multidisciplinary approach are important keys to prevent adverse obstetric outcomes. **2019**, 32, 1292-1298

3

148 Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part I: Diagnosis, Evaluation and Treatment. **2020**, 16, 71-86

4

147 Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part II: Obstetric Antiphospholipid Syndrome and Special Situations. **2020**, 16, 133-148

3

146 Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. **2020**, 59, 146-152

6

145 Role of direct oral anticoagulants in patients with kidney disease. **2020**, 97, 664-675

14

144 Use of direct oral anticoagulants in antiphospholipid syndrome: Reply. **2020**, 18, 259-261

5

143 Recommendations of the Spanish Rheumatology Society for primary antiphospholipid syndrome. Part I: Diagnosis, evaluation and treatment. **2020**, 16, 71-86

142 Recommendations of the Spanish Rheumatology Society for primary antiphospholipid syndrome. Part II: Obstetric antiphospholipid syndrome and special situations. **2020**, 16, 133-148

141 Managing pregnancy-associated clinical emergencies in systemic lupus erythematosus: a case-based approach. *Expert Review of Clinical Immunology*, **2020**, 16, 5-22

5.1 1

140 Neuropsychiatric SLE: From Immune Mechanisms to Clinical Management. **2020**,

1

139 Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. **2020**, 10, CD012169

8

138 Thrombin generation in subjects with lupus anticoagulant without prior thrombosis or gestational morbidities. **2020**, 196, 425-431

2

137 Management of Antiphospholipid Syndrome. **2020**, 8,

7

136	A glimpse into the history of description of the antiphospholipid syndrome. <i>Lupus</i> , <b>2020</b> , 29, 1493-1502	2.6	
135	Síndrome de anticuerpos antifosfolípidos. <b>2020</b> , 24, 1-5		
134	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <b>2020</b> , 18, 2126-2137	30	
133	ADRENAL INSUFFICIENCY SECONDARY TO BILATERAL ADRENAL HEMORRHAGE ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME. <b>2020</b> , 6, e65-e69	0	
132	Síndrome da anticorpi antifosfolipidi. <b>2020</b> , 22, 1-6		
131	Ischemic Stroke in a Young Patient with Nephrotic Syndrome and Antiphospholipid Syndrome. <b>2020</b> , 2020, 8828864	1	
130	Atypical Presentation of Anti-Phospholipid Antibody Syndrome with Seizure and Atrial Mass. <b>2020</b> , 2020, 8877445		
129	Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis. <b>2020</b> , 18, 2274-2286	8	
128	Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: A meta-analysis. <b>2020</b> , 79, 43-50	6	
127	Antiphospholipid syndrome and challenges with direct oral anticoagulants. <b>2020</b> , 81, 1-11	0	
126	[Antiphospholipid syndrome : Update on diagnostics and management]. <b>2020</b> , 79, 255-266	3	
125	Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management. <i>Haematologica</i> , <b>2020</b> , 105, 562-572	6.6	43
124	Pediatric APS: State of the Art. <b>2020</b> , 22, 9		11
123	Visual recovery and vascular reperfusion after vaso-occlusive retinopathy from anti-phospholipid syndrome associated with systemic lupus erythematosus. <b>2020</b> , 19, 100763	2	
122	How I treat unexplained arterial thrombosis. <b>2020</b> , 136, 1487-1498	6	
121	What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome?. <b>2020</b> , 189, 216-227	9	
120	Precision medicine and the antiphospholipid syndrome: what is the future?. <b>2020</b> , 39, 1015-1017	1	
119	The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. <b>2020</b> , 19, 102491	38	

- 118 Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review. **2020**, 104, 519-525 5
- 117 Subarachnoid Hemorrhage After Ischemic Stroke Associated with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. **2020**, 136, 248-252 3
- 116 The antiphospholipid syndrome - often overlooked cause of vascular occlusions?. **2020**, 287, 349-372 14
- 115 Anaesthetic considerations for patients with antiphospholipid syndrome undergoing non-cardiac surgery. **2020**, 48, 300060519896889 5
- 114 An update on the management of antiphospholipid syndrome. **2020**, 12, 1759720X20910855 11
- 113 Managing thromboembolic risk in patients with hereditary and acquired thrombophilias. **2020**, 135, 344-350 9
- 112 Acute Myocardial Infarction Due to Antiphospholipid Syndrome - Case Report and Review of the Literature. **2021**, 46, 100552 1
- 111 Distinguishing aortic valve thrombus from Libman-Sacks endocarditis in antiphospholipid syndrome: imaging and management. **2021**, 17, 101-111
- 110 Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review. **2021**, 48, 100788 2
- 109 Thrombosis in Rheumatological Diseases. **2021**, 263-289
- 108 Nervous System and Rheumatology. **2021**, 177-190
- 107 Management of Women with Antiphospholipid Antibodies or Antiphospholipid Syndrome during Pregnancy. **2021**, 36, e24 3
- 106 Antiphospholipid-Syndrom bei Kindern und Jugendlichen. *Springer Reference Medizin*, **2021**, 1-18 0
- 105 Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management. **2021**, 23, 10 1
- 104 Early Initiation of Anticoagulation Improves the Long-Term Prognosis in Patients With Antiphospholipid Syndrome Associated Portal Vein Thrombosis. **2021**, 8, 630660
- 103 Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. **2021**, 54, 37-45 2
- 102 Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?. **2021**, 9, 5
- 101 Deficiency of natural anticoagulants: how should we manage cardiovascular prevention?. **2021**, 16, 813-814

100	ANTIPHOSPHOLIPID ANTIBODIES DO NOT PREDICT DAMAGE IN SLE PATIENTS IN THE XXI CENTURY. AN OBSERVATIONAL STUDY FROM THE LUPUS-CRUCES COHORT. <b>2021</b> ,	0
99	Risk factors for ischemic antiphospholipid syndrome: A case-control study. <b>2021</b> , 202, 106492	1
98	Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis. <b>2021</b> , 47, 709-723	2
97	A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter. <b>2021</b> , 8, 683357	5
96	Challenging endovascular treatment for the patient with chronic limb threatening ischemia due to antiphospholipid syndrome.. <i>Journal of Cardiology Cases</i> , <b>2021</b> , 24, 276-279	0.6 1
95	Direct oral anticoagulant use in special populations. <b>2021</b> , 27, 311-318	
94	Use of hydroxychloroquine to control immune response and hypercoagulability in patients with primary antiphospholipid syndrome. <b>2021</b> , 90, 114-115	0
93	Adrenal hemorrhage and hemorrhagic masses; diagnostic workup and imaging findings. <b>2021</b> , 94, 20210753	0
92	Secondary Erosive Arthritis in a Young Lady - A Rare Manifestation of Primary Antiphospholipid Antibody Syndrome. <b>2021</b> , 11, 15-18	1
91	Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers. <b>2021</b> , 9,	2
90	Inferior Vena Cava Filters in the Management of Venous Thromboembolism. 114-127	1
89	Prevention and Treatment of Thrombotic Antiphospholipid Syndrome. <b>2017</b> , 223-233	4
88	Treatment of Non-criteria Manifestations in Antiphospholipid Syndrome. <b>2017</b> , 247-266	4
87	Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis. <b>2017</b> , 77-116	3
86	Vaskulitis und Vaskulopathien. <b>2012</b> , 1054-1085	2
85	Antiphospholipid syndrome. <b>2015</b> , 1144-1152	5
84	Use of Vena Cava Filters and Venous Access Devices. <b>2013</b> , 563-594	1
83	Antiphospholipid syndrome - an update. <b>2018</b> , 47, 451-464	40

82	Inferior vena cava filter - comprehensive overview of current indications, techniques, complications and retrieval rates. <b>2020</b> , 49, 449-462	13
81	Digital ischaemia secondary to adalimumab-induced antiphospholipid syndrome. <b>2020</b> , 13,	3
80	Coronary Artery Thromboses, Stent Thrombosis and Antiphospholipid Antibody Syndrome: Case Report. <b>2018</b> , 9, 129-132	6
79	The Issue of the Antiphospholipid Antibody Syndrome. <b>2020</b> , 12, 286-292	6
78	[Adrenal hemorrhage in a patient with systemic lupus erythematosus]. <b>2019</b> , 51, 1178-1181	3
77	Sarcoidosis and Antiphospholipid Syndrome: A Systematic Review of Cases. <b>2015</b> , 7, 379-83	4
76	Recurrent Stroke Due to Antiphospholipid Syndrome Remitted by Immunotherapy, Not by Anticoagulation Therapy: A Case Report and Literature Review. <b>2019</b> , 22, 250-252	1
75	Liver transplantation in a patient with primary antiphospholipid syndrome and Budd-Chiari syndrome. <b>2015</b> , 7, 2229-36	15
74	Comparison of the Therapeutic Effects of Rivaroxaban Versus Warfarin in Antiphospholipid Syndrome: A Systematic Review. <b>2020</b> , 35, 107-116	2
73	Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. <b>2021</b> ,	4
72	Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome. <b>2021</b> , 13, e19009	1
71	Acute Neurologic Manifestations of Systemic Immune-Mediated Diseases. <b>2021</b> , 41, 541-553	
70	Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome. <b>2012</b> , 167-179	
69	Task Force Report on Non-criteria Manifestations: Nephropathy. <b>2012</b> , 207-221	1
68	Hot topics in lupus pregnancy. <b>2013</b> , 3, 32	
67	Comment gérer la grossesse et l'allaitement d'une patiente lupique et/ou ayant un syndrome des antiphospholipides ?. <b>2013</b> , 153-165	
66	Que faire en présence d'anticorps antiphospholipides chez un malade lupique sans passé thrombotique ni obstétrical ?. <b>2013</b> , 99-102	
65	Venous Thromboembolic Disease. <b>2014</b> , 511-529	1

64 Thrombotic Risk Factors. **2014**, 185-202

63 Systemic Lupus Erythematosus and Antiphospholipid Syndrome. **2014**, 2, 544-549

62 Classification Criteria for the Antiphospholipid Syndrome. **2015**, 47-59

61 New Treatments. **2015**, 219-232

60 Antiphospholipid Antibody Carriers. **2015**, 207-218

59 APS and the Nervous System. **2015**, 89-102

58 Systemic Thromboembolism in Pregnancy: Cerebrovascular Disease. **2015**, 105-124

57 Systemic lupus erythematosus. **2015**, 1112-1126

1

56 Clinical case of rheumatoid arthritis with antiphospholipid antibody syndrome. **2015**, 6, 70-78

55 Primary antiphospholipid syndrome presenting as Budd-Chiari syndrome. **2016**, 23, 337-338

54 Antiphospholipid Antibody Syndrome in Childhood. **2017**, 377-392

53 Pediatric and Neonatal Lupus. **2017**, 333-344

52 Antiphospholipid Syndrome: What Should Patients Know?. **2017**, 341-357

0

51 Specific issues. **2018**, 121-150

50 Antiphospholipid syndrome. **2018**, 29, 294-306

49 An unusual case of heart attack. **2018**, 18, 7-13

48 Manifestações neurológicas da síndrome do anticorpo antifosfolípido. **2018**, 12-17

47 Lupus Nephritis. **2019**, 153-168

46	Management of antiphospholipid syndrome in adults: The European League Against Rheumatism (EULAR) recommendations. <b>2019</b> , 53, 144-150		
45	[Genetic causes of stroke in young patients]. <b>2019</b> , 119, 102-109		
44	DIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME IN PEOPLE WITH CLINICAL CRITERIA OF THE DISEASE. EXPERIENCE OF A SEPARATE OUTPATIENT CENTER. <b>2019</b> , 92-98		
43	Pulmonary involvement in antiphospholipid syndrome. <b>2019</b> , 124-139		
42	Neurovascular Consequences of Systemic Disease: Lupus and Primary Hyperparathyroidism. <b>2020</b> , 303-335		
41	Spinal and cerebral hematoma in systemic lupus erythematosus and antiphospholipid syndrome: is drug interaction the culprit?. <i>Drug Metabolism and Personalized Therapy</i> , <b>2020</b> ,	2	
40	Pregnancy Management in Women with Antiphospholipid Syndrome. <i>Médica</i> , <b>2019</b> , 14, 148-160		2
39	Idiopathic Normal Pressure Hydrocephalus - What We Know. <i>Médica</i> , <b>2019</b> , 14, 161-164		1
38	[Mechanisms and management of thrombosis and bleeding in antiphospholipid syndrome]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , <b>2017</b> , 38, 994-996	0.4	
37	Antiphospholipid syndrome with mesenteric vein thrombosis and hepatic nodular regenerative hyperplasia in a child: A case report.. <i>Medicine (United States)</i> , <b>2021</b> , 100, e28105	1.8	0
36	RESPIRATORY SYSTEM DISORDERS IN ANTIPHOSPHOLIPID SYNDROME (CLINICAL CASE). <b>2021</b> , 78, 181-184		
35	Cognitive Impairment in Anti-Phospholipid Syndrome and Anti-Phospholipid Antibody Carriers.. <i>Brain Sciences</i> , <b>2022</b> , 12,	3.4	0
34	Author's replyValidity of current treatment guideline for patients with limb-threatening ischemia with antiphospholipid syndrome. <i>Journal of Cardiology Cases</i> , <b>2022</b> ,	0.6	
33	There is no consensus among guidelines/consensus reports concerning the optimal management of patients with antiphospholipid syndrome and an arterial event. <i>Journal of Cardiology Cases</i> , <b>2022</b> ,	0.6	
32	Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects.. <i>Paediatric Drugs</i> , <b>2021</b> , 24, 13	4.2	
31	Unexplained arterial thrombosis: approach to diagnosis and treatment. <i>Hematology American Society of Hematology Education Program</i> , <b>2021</b> , 2021, 76-84	3.1	0
30	Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome-Multicenter, Real-Life Long-Term Follow-Up.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 843718	8.4	0
29	Antiphospholipid Syndrome and Stroke.		



28	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 842923	8.4	
27	Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 824775	5.6	
26	Image_1.TIF. <b>2018</b> ,		
25	Image_2.TIF. <b>2018</b> ,		
24	Image_3.TIF. <b>2018</b> ,		
23	Image_4.TIF. <b>2018</b> ,		
22	Image_5.TIF. <b>2018</b> ,		
21	Antiphospholipid-Syndrom bei Kindern und Jugendlichen. <i>Springer Reference Medizin</i> , <b>2022</b> , 533-549		o
20	What are the prospects for antiplatelet agents for thromboprophylaxis in antiphospholipid syndrome?. <i>Expert Review of Clinical Immunology</i> , 1-3	5.1	
19	Lack of efficacy of direct oral anticoagulants compared to warfarin in antiphospholipid antibody syndrome.. <i>Haematologica</i> ,	6.6	o
18	Moyamoya Syndrome Presenting with Ischemic Stroke Caused by Rapid Worsening of Vessel Stenosis Associated with Triple-seropositive Antiphospholipid Syndrome: A Case Report. <b>2022</b> ,		o
17	Pathophysiology of Placenta in Antiphospholipid Syndrome. <b>2022</b> , 2, 66-79		
16	Bilateral adrenal haemorrhage in antiphospholipid syndrome and a short review of the literature. <b>2022</b> , 15, e251199		o
15	Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (Registry) 096120332211287		o
14	How we treat clinical dilemmas in antiphospholipid syndrome: A case-based approach. <b>2022</b> ,		o
13	Therapeutische Aspekte beim Antiphospholipidsyndrom.		o
12	Research trends and frontiers on antiphospholipid syndrome: A 10-year bibliometric analysis (2012-2021). 13,		o
11	Acute coronary syndromes in Antiphospholipid syndrome-above suspicion: a systematic review. <b>2022</b> , 101503		o

- 10 Incomplete systemic lupus erythematosus: terminology, diagnosis, course and therapy. **2022**, 100, 447-455 ○
- 9 Brainstem stroke in a patient with systemic lupus erythematosus and triple antiphospholipid antibody profile. **2022**, 15, e254147 ○
- 8 Update on the Diagnosis and Anticoagulant Treatment of the Antiphospholipid Syndrome. 101-111 ○
- 7 Interference in point-of-care international normalized ratio monitoring in patients with lupus anticoagulant is correlated with anti- $\beta$ -glycoprotein I antibody titers. **2023**, 7, 100011 ○
- 6 Antiphospholipid Syndrome and the Lungs. 76-82 ○
- 5 Demographic, Clinical, and Serological Characteristics of Antiphospholipid Syndrome Patients From the Anticoagulation Clinic of Hospital Universitario San Vicente Fundaci3n, Medell3n, Colombia. **2023**, ○
- 4 Hematology and Coagulation. **2013**, 131-147.e6 ○
- 3 Egyptian recommendations for the management of systemic lupus erythematosus: a consensus, evidence-based, clinical practice guidelines for treat-to-target management. **2023**, 50, ○
- 2 Prevalence of Polymorphisms of Genes Responsible for Coagulation System and Folate Metabolism and Their Predictive Value for Thrombosis Development in MINOCA Patients: Immediate and Long-Term Prognoses. **2023**, 13, 47-60 ○
- 1 Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sj3gren3 syndrome: evidence- and practice-based guidance. 14, ○